Dasatinib

Name: Dasatinib
Brand: Selleck Chemicals
SKU: S1021
Rating: 5 (308 reviews)

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

308 publications

CAS No. 302962-49-8

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Selleck's Dasatinib has been cited by 308 publications

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )
Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2730

PubMed: 32977582 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):270

PubMed: 32631432 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )
Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16616

PubMed: 33024173 ( click the link to review the publication )

Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):139

PubMed: 32792487 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )
Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )
Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31405946 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )
FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )
J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )
EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )
Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )
Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )
Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	NUD5[W9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW3NkBp	MnnmSG1UVw>?	NGHyNXlKSzVyPUCuNFAxODdizszN	M1O5XVE4QTV4MEiw
K562	NFrQRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYW2dIdlPzJiaB?=	M1TtNGROW09?	NVrhc4QyUUN3ME2wMlAxOSEQvF2=	NF3F[mMyPzl3NkC4NC=>
M07e	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmWzO\|IhcA>?	MlLsSG1UVw>?	NHvZWpBKSzVyPUCuNFAyOiEQvF2=	NEnUXpMyPzl3NkC4NC=>
ALL3	Mo\sR5l1d3SxeHnjJGF{e2G7	M1zOXVAvOc7:TR?=	M3rtUFczKGh?	MWPEUXNQ	MoDsTWM2OD1yLkCwNFQh\|ryP	NEW5XYIyQTh6OUW0NC=>
CML	M4Psdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXmyNEBucW5?	MoT6SG1UVw>?	MWTJR\|UxRTBwMECxJO69VQ>?	MUmxPVIyQTBzNh?=
BA/F3	M3;Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEPyUm84OiCq	NUDL[3ZoTE2VTx?=	MXHJR\|UxRTZwNUi5JO69VQ>?	NVzKO2I{OjNyOEi2OFQ>
BA/F3	NUfSdIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnL4O\|IhcA>?	NXP1OVU6TE2VTx?=	MUfJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?=	NEL2UpAzOzB6OE[0OC=>
BA/F3	NVq0eFNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XNSlczKGh?	M1zhOWROW09?	MmfXTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>?	NIe2cYEzOzB6OE[0OC=>
BA/F3	NWrZU2pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlXzO\|IhcA>?	MYDEUXNQ	MYPJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1?	NH;3OFAzOzB6OE[0OC=>
BA/F3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWC3NkBp	MX3EUXNQ	M{\1RWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6\|ryP	MVOyN\|MxOTdyMx?=
BA/F3	M{PSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4raXFczKGh?	NUTw[XYyTE2VTx?=	NIrkXZRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA{Os7:TR?=	NYDaUnQ{OjN\|MEG3NFM>
BA/F3	NWnNV2huT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkfFO\|IhcA>?	MVXEUXNQ	M2G5Z2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy\|ryP	NV3HeJZOOjN\|MEG3NFM>
BA/F3	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH7BeXo4OiCq	NFzlNGRFVVOR	MnrtTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>?	NITNcIwzOzNyMUewNy=>
BA/F3	M2Lr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1fhVlczKGh?	MYDEUXNQ	MVPJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>?	M4rzWFI{OzBzN{Cz
BA/F3	NEP1T3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEfTPFQ4OiCq	MnfMSG1UVw>?	MnziTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0>	NIPyT2UzOzNyMUewNy=>
BA/F3	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2nFOlczKGh?	M1[3RmROW09?	MlzSTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1?	MU[yN\|MxOTdyMx?=
BA/F3	NXTHcXQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkLHO\|IhcA>?	NHzVfmZFVVOR	M1f1T2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR\|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO	M2C3[lI{OzBzN{Cz
BA/F3	NUD5dphjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGq0[3A4OiCq	MVPEUXNQ	NXnGRY5SUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN	M2PYTVI{OzBzN{Cz
T cell	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4\kU\|czKGh?	M2\2RmROW09?	MX\Jcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=>	M{X6b\|E4OTV2NUGy
WiDr	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGDTbG44OiCq	M2rlUWROW09?	NYfiPJd6UUN3ME2wMlA2OiEQvF2=	NYLUdFhuOTV4MUW1NVI>
PC3	NIfx[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoDLO\|IhcA>?	NHXrWpRFVVOR	NIrLbm9KSzVyPUCuNFA6PCEQvF2=	NW\oTINVOTV4MUW1NVI>
MDA-MB-231	NYDkN4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWK3NkBp	Mmi0SG1UVw>?	NGDLcYlKSzVyPUCuNFEzKM7:TR?=	M1LXZ\|E2PjF3NUGy
Hs578T	M3;rN2N6fG:2b4jpZ{BCe3OjeR?=		MmD1O\|IhcA>?	MmewSG1UVw>?	Ml7QS2k2OD1yLkCzJO69VQ>?	Ml7qNlQxOTV\|Mke=
HMEC	MYTDfZRwfG:6aXOgRZN{[Xl?		MnzTO\|IhcA>?	M4\CSWROW09?	NHzIdFVIUTVyPUGuPEDPxE1?	NIXvRpEzPDBzNUOyOy=>
DU145	MXjDfZRwfG:6aXOgRZN{[Xl?		M2PCdVczKGh?	NE\qT4lFVVOR	NUnTU2ZiT0l3ME2wMlE3KM7:TR?=	NFvwcFEzPDBzNUOyOy=>
U251	NEHzSHJEgXSxdH;4bYMhSXO\|YYm=		M2S1PVczKGh?	MYDEUXNQ	M3e1WmdKPTB;Mj64NUDPxE1?	NHHpXJUzPDBzNUOyOy=>
NCI60	Mny5R5l1d3SxeHnjJGF{e2G7		MnPmO\|IhcA>?	MkXPSG1UVw>?	NUfkR3I3T0l3ME21Mlch\|ryP	M1fQflI1ODF3M{K3
MALME-3M	NWOxbI1bS3m2b4TvfIlkKEG\|c3H5		MXe3NkBp	NEHWXGxFVVOR	M2X6OWdKPTB;Nj62NUDPxE1?	M{DMT\|I1ODF3M{K3
KM12	M3K1TWN6fG:2b4jpZ{BCe3OjeR?=		M4TCVFczKGh?	MYXEUXNQ	NXzhbFFST0l3ME23MlQ1KM7:TR?=	NGf2T2IzPDBzNUOyOy=>
SW620	MYrDfZRwfG:6aXOgRZN{[Xl?		NHPXfJc4OiCq	MoLvSG1UVw>?	NVvFOJJ{T0l3ME24MlQ{KM7:TR?=	NFO3ToMzPDBzNUOyOy=>
RXF 393NL	M4H2NGN6fG:2b4jpZ{BCe3OjeR?=		NI\qeXA1KGSjeYO=	NIjpO4JFVVOR	MVTJR\|UxRTBwMEKxO{DPxE1?	NUnN[VJMOjN{NUOwO\|Q>
LXFA 983L	MUDDfZRwfG:6aXOgRZN{[Xl?		NHy1U3Q1KGSjeYO=	M2f5ZmROW09?	MlPnTWM2OD1yLkC1OlUh\|ryP	MUWyN\|I2OzB5NB?=
PRXF DU145	MYjDfZRwfG:6aXOgRZN{[Xl?		M4XHWlQh\GG7cx?=	NUfoUJRZTE2VTx?=	NIqzRoJKSzVyPUCuNFYzOyEQvF2=	NV\yXYdxOjN{NUOwO\|Q>
PAXF 1657L	NH\HUnBEgXSxdH;4bYMhSXO\|YYm=		M1y0VlQh\GG7cx?=	NG\QSo1FVVOR	M4rtXmlEPTB;MD6xNlEh\|ryP	NIr6[4wzOzJ3M{C3OC=>
CXF 1103L	NIXTe3hEgXSxdH;4bYMhSXO\|YYm=		M{jPfVQh\GG7cx?=	NH\pNlBFVVOR	M1XTdGlEPTB;ND6zOkDPxE1?	MX2yN\|I2OzB5NB?=
GXF251L	MVvDfZRwfG:6aXOgRZN{[Xl?		MVe0JIRigXN?	M13sNGROW09?	Mn;YTWM2OD1{LkK1JO69VQ>?	M{DBNFI{OjV\|MEe0
NCI-H23	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH7IeHc4OiCq	NFn0VGdFVVOR	MoPLTWM2OD1{LkK3JO69VQ>?	MkPCNlM2OjFyMkC=
HCT116	M4W5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYe3NkBp	Mn3tSG1UVw>?	M13wZWlEPTB;Mj6zJO69VQ>?	MWqyN\|UzOTB{MB?=
MCF7	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPkU4NpPzJiaB?=	MlPySG1UVw>?	M4TqPWlEPTB;Mj61O{DPxE1?	MXSyN\|UzOTB{MB?=
NCI-H460	NY[wZYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlzyO\|IhcA>?	MV7EUXNQ	NF;CclBKSzVyPUiuPVkh\|ryP	NXXQeIJCOjN3MkGwNlA>
DLD1	NESzXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGW3VYw4OiCq	NIfUPXFFVVOR	NYPNWW9tUUN3ME20MlYh\|ryP	M2T5bFI{PTZ5OU[w
NCI-H661	NUnR[2RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPpfGJDPzJiaB?=	NXjZcZJQTE2VTx?=	NIj4U2hKSzVyPUeuPEDPxE1?	NFH6cFYzOzV4N{m2NC=>
A549	NEDKZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXzaSoR[PzJiaB?=	NUHRTXZWTE2VTx?=	MnjGTWM2OD16LkKg{txO	M1TMO\|I{PTZ5OU[w
U937	NFzubWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXLMUohPPzJiaB?=	NY\jcYY2TE2VTx?=	M1freWlEPTB;MUKuNkDPxE1?	M1TYXVI{PTZ5OU[w
HEK293	Ml7KSpVv[3Srb36gRZN{[Xl?	MmT1NVDDqM7:TR?=		MX\EUXNQ	MVzJcoR2[2W\|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?=	Mne0NlI4PzB4MUC=
HUVEC	MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjjRYIxNjF3wrFOwG0>	NU[0cGFkPzJiaB?=	MUDEUXNQ	NGqxSoFKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0>	MmXXNlI5PTN7OUO=
HUVEC	MX3GeY5kfGmxbjDBd5NigQ>?	M1zoVFE2yqEQvF2=	MVe3NkBp	MlTRSG1UVw>?	NXy4SFhuUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1?	NF;rW4YzOjh3M{m5Ny=>
Plasmodium falciparum	NEHFVWJHfW6ldHnvckBCe3OjeR?=	NFLi[VMyOMLizszN	NF\jeVYyPSCvaX6=	MkTLSG1UVw>?	NF\aTHZKdmirYnn0d{BRdGG\|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR\|UxKG:oIEGuNVfPxE1?	MlnRNlQ2PTB\|M{C=
PC3	MmDRSpVv[3Srb36gRZN{[Xl?	MYWwMlEh\|ryP	M2DCdVUhcA>?	MYTEUXNQ	NHTFblhKdmirYnn0d{BpfW2jbjDQR\|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2=	NUHaVXVsOTl2NkK5O\|U>
DU145	M3TzcmZ2dmO2aX;uJGF{e2G7	M{TxTFAvOSEQvF2=	Mm\uOUBp	M33sXmROW09?	MUjJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	MoTSNVk1PjJ7N{W=
PC3	M3PhUmtqdmG\|ZTDBd5NigQ>?	NYX0SXV6OC5zIN88US=>	M3;vZ\|UhcA>?	MX\EUXNQ	NVzVSm46UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=>	M2\ybFE6PDZ{OUe1
DU145	NHXLdmNMcW6jc3WgRZN{[Xl?	MW[wMlEh\|ryP	MWe1JIg>	MWHEUXNQ	NUeydHJHUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O	M3;BSFE6PDZ{OUe1
PC3	MUHLbY5ie2ViQYPzZZk>	NGnQbmQxNjFizszN	MUe1JIg>	MVnEUXNQ	M1rnRWlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NUDjNFh1OTl2NkK5O\|U>
DU145	MYrLbY5ie2ViQYPzZZk>	NUj3S\|JGOC5zIN88US=>	M1HlPFUhcA>?	MULEUXNQ	MYHJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NEfxR5UyQTR4Mkm3OS=>
Huh7	NGi4T\|hCdnSrdnnyZYwhSXO\|YYm=	NF7aO5EzNjVizszN	M{fISVQh\GG7cx?=	NYniXIJITE2VTx?=	M2jje2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=	MYSxO\|M3ODZ5Nh?=
C6/36	M3nubmFvfGm4aYLhcEBCe3OjeR?=	NF34cHgzNjVizszN	M2q0XlQh\GG7cx?=	NVnOUWtFTE2VTx?=	MVzJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO	MoLWNVc{PjB4N{[=
U937	NHr4RVVHfW6ldHnvckBCe3OjeR?=	MV6xJO69VQ>?	MnzFNUBp	MXHEUXNQ	MX;S[YR2[2W\|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl\|NzDj[Yxtew>?	MlG4NVc3QDRyOUm=
U937	M1PUd2Z2dmO2aX;uJGF{e2G7	M3HNd\|Eh\|ryP	MUOxJIg>	MVXEUXNQ	Mln0VoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>	NYPyUWQ2OTd4OESwPVk>
murine mast cell	NIDrSWNHfW6ldHnvckBCe3OjeR?=	MlrnNUDPxE1?	NVfmXmE1OjRiaB?=	M4XCPGROW09?	Mkj6TY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy\|IHH0JFEhfU1?	NEDnOXgyPzZ6NEC5PS=>
BV-173	M4D5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{G1fGlEPTB;MD6wNFAxODBzMEmg{txO	MV\TRW5ITVJ?
K-562	NH;Zc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHX6UpZKSzVyPUCuNFAxODByMk[2JO69VQ>?	MoryV2FPT0WU
BL-70	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mom1TWM2OD1yLkCwNFAxODh{MjFOwG0>	MXfTRW5ITVJ?
EM-2	M4H0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7kT2lOUUN3ME2wMlAxODByMUC4JO69VQ>?	MYrTRW5ITVJ?
LAMA-84	M1;NOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrCSmlKSzVyPUCuNFAxODB\|MkGg{txO	M{Dn[3NCVkeHUh?=
MEG-01	NUjIOJNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTBwMECwNFA6QCEQvF2=	MkjsV2FPT0WU
EoL-1-cell	NV3YXmtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfkTWM2OD1yLkCwNFAyOzFizszN	M13l[3NCVkeHUh?=
CTV-1	M4nj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHOyPFZKSzVyPUCuNFAxODRyNDFOwG0>	MkL2V2FPT0WU
TE-15	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTSUWdKSzVyPUCuNFA2QDlizszN	NVTEO5lsW0GQR1XS
NOS-1	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzQb4dMUUN3ME2wMlAxPjF\|IN88US=>	MmfLV2FPT0WU
D-336MG	NFnsTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTBwMEC2N{DPxE1?	NVvjdIZUW0GQR1XS
LB1047-RCC	M1nlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHIS\|VZUUN3ME2wMlAxQTh7IN88US=>	MofoV2FPT0WU
LB996-RCC	NIXE[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1z5c2lEPTB;MD6wNFk6OSEQvF2=	MmjTV2FPT0WU
SW982	NXrVdItQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DDOGlEPTB;MD6wNVEyPSEQvF2=	NFixeo9USU6JRWK=
TK10	MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYG1SlExUUN3ME2wMlAyOTd2IN88US=>	MmDBV2FPT0WU
A704	NXiwZlFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnnU2k2UUN3ME2wMlAyPDlzIN88US=>	M4P3VHNCVkeHUh?=
TE-8	M{Gydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HkWGlEPTB;MD6wNVU4PiEQvF2=	MV3TRW5ITVJ?
DOHH-2	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXiTWM2OD1yLkCxO\|E6KM7:TR?=	MmrGV2FPT0WU
HOP-62	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPTTWM2OD1yLkCxPFM1KM7:TR?=	M2HXcHNCVkeHUh?=
TE-12	M{LO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;6NHFKSzVyPUCuNFE5PjFizszN	MlHPV2FPT0WU
KGN	NWDxdG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTBwMEG5OFIh\|ryP	NYnr[3A{W0GQR1XS
NCI-H1648	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLTTWM2OD1yLkCyNFEyKM7:TR?=	M4fYcXNCVkeHUh?=
OS-RC-2	MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[5ZlRKSzVyPUCuNFIxOyEQvF2=	MW\TRW5ITVJ?
GB-1	M4e3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTBwMEKxOVch\|ryP	MoDDV2FPT0WU
RXF393	MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfrTWM2OD1yLkCyN\|U4KM7:TR?=	MnH3V2FPT0WU
LC-2-ad	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPxTI9KSzVyPUCuNFI2QDZizszN	MXvTRW5ITVJ?
KS-1	M133fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXjd2FsUUN3ME2wMlAzPzNizszN	MUDTRW5ITVJ?
ETK-1	NVXtOYZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmj0TWM2OD1yLkCyPFMzKM7:TR?=	M4TiO3NCVkeHUh?=
SW954	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoC5TWM2OD1yLkCyPVI4KM7:TR?=	NYfLdmN5W0GQR1XS
Becker	M3HHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfzTZJKSzVyPUCuNFMxODNizszN	NV;kTnZUW0GQR1XS
MZ1-PC	NIjrWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7icHFKSzVyPUCuNFMyOTlizszN	NHfI[IFUSU6JRWK=
ES6	NV7VTGRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX[5[pNHUUN3ME2wMlA{OTl\|IN88US=>	M{XYSXNCVkeHUh?=
KURAMOCHI	NH;QVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvCVVlvUUN3ME2wMlA{PDh5IN88US=>	NVXrWZJSW0GQR1XS
CGTH-W-1	NFr2c3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr3OmdKSzVyPUCuNFM2PDhizszN	Mo[1V2FPT0WU
VA-ES-BJ	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPCR2FKSzVyPUCuNFM6ODJizszN	NWf5W3E2W0GQR1XS
LXF-289	NHnMR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTBwMEO5OVYh\|ryP	MmnoV2FPT0WU
MPP-89	M{POZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjhTWM2OD1yLkC0NFQ6KM7:TR?=	MVXTRW5ITVJ?
SW872	M4LqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\DSlBKSzVyPUCuNFQyPjFizszN	MkfWV2FPT0WU
SNB75	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnq1TWM2OD1yLkC0OFM2KM7:TR?=	M{mzRnNCVkeHUh?=
PSN1	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf4ZZoyUUN3ME2wMlA1PDd2IN88US=>	NHX5TG1USU6JRWK=
LB831-BLC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnsVohUUUN3ME2wMlA1PjB7IN88US=>	M4K5WHNCVkeHUh?=
MFH-ino	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vQWWlEPTB;MD6wOFczPCEQvF2=	NYSzPFZbW0GQR1XS
TGBC24TKB	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWn4NHJGUUN3ME2wMlA1PzZzIN88US=>	Mnf2V2FPT0WU
A388	NWnaUZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwMEWwPVUh\|ryP	M3LPZnNCVkeHUh?=
BB30-HNC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\wVFlKSzVyPUCuNFU1OzdizszN	Ml\lV2FPT0WU
GI-ME-N	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHpOnhKSzVyPUCuNFYyOThizszN	MYDTRW5ITVJ?
TGBC1TKB	M1v6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvvbJdKSzVyPUCuNFYyPjRizszN	NIPtO5VUSU6JRWK=
TE-10	NGnreXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PreWlEPTB;MD6wOlM2PyEQvF2=	MWPTRW5ITVJ?
A498	NXLLToNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTBwMEeyPFQh\|ryP	MY\TRW5ITVJ?
TE-11	M{jRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfMeGRKSzVyPUCuNFc5PThizszN	NGD6WZdUSU6JRWK=
BB65-RCC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TyTmlEPTB;MD6wPFIzPyEQvF2=	MoHpV2FPT0WU
C2BBe1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjNS4xHUUN3ME2wMlA5OzB6IN88US=>	NGXCe2hUSU6JRWK=
NCI-H747	NVLDPIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTBwMEizOlIh\|ryP	M3TZO3NCVkeHUh?=
IST-MES1	M3nGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HX[WlEPTB;MD6wPFU2OiEQvF2=	M1jQSnNCVkeHUh?=
KALS-1	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XDOWlEPTB;MD6wPVQ6KM7:TR?=	M{fvSnNCVkeHUh?=
GCIY	NET3bpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXvTnNKSzVyPUCuNFk3PTZizszN	NWLt[pJYW0GQR1XS
RL95-2	NYXFfY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3JT4lKSzVyPUCuNVA{QCEQvF2=	M3TtXHNCVkeHUh?=
TE-1	MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrLbmZjUUN3ME2wMlExPTRizszN	NITnXYhUSU6JRWK=
NCI-H1355	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jzcGlEPTB;MD6xNVAzQCEQvF2=	NVnuc4JQW0GQR1XS
SW962	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkexTWM2OD1yLkGxNlkzKM7:TR?=	MXvTRW5ITVJ?
KLE	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYe0R21{UUN3ME2wMlEyOzF5IN88US=>	NI\KSHVUSU6JRWK=
MC116	MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPFdXlKSzVyPUCuNVE1OSEQvF2=	M4DFUXNCVkeHUh?=
NMC-G1	M1q2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7Pcm9KSzVyPUCuNVE3ODZizszN	NHn1V5VUSU6JRWK=
KU812	MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moe0TWM2OD1yLkGxPFg{KM7:TR?=	M2fwUnNCVkeHUh?=
COLO-829	NUnUO2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTBwMUKyNVMh\|ryP	MUHTRW5ITVJ?
NTERA-S-cl-D1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XqbmlEPTB;MD6xNlI5OyEQvF2=	MUPTRW5ITVJ?
IST-MEL1	NFztR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDZTWM2OD1yLkGzOFUh\|ryP	M{LuNXNCVkeHUh?=
MLMA	MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTBwMUSwN\|Ih\|ryP	M{XKNXNCVkeHUh?=
LS-123	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LLT2lEPTB;MD6xOFA3PCEQvF2=	MnLZV2FPT0WU
LB2518-MEL	NWD0d2hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DJW2lEPTB;MD6xOFE3OiEQvF2=	NWjOVohxW0GQR1XS
NB69	NELaTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkj5TWM2OD1yLkG0OFM3KM7:TR?=	MmmzV2FPT0WU
8-MG-BA	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe3ZohmUUN3ME2wMlE2PDV6IN88US=>	MnXwV2FPT0WU
K5	NFG5b2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PRPGlEPTB;MD6xOlQ5QSEQvF2=	M4rnPXNCVkeHUh?=
KINGS-1	NXy3W2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXoN4p7UUN3ME2wMlE3PjZ4IN88US=>	M1XHN3NCVkeHUh?=
SF268	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTBwMUe0NFQh\|ryP	MYrTRW5ITVJ?
PF-382	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTBwMUe2O\|gh\|ryP	NHPMV5RUSU6JRWK=
SH-4	NGS0OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTBwMUi0NVMh\|ryP	M3;GbXNCVkeHUh?=
NALM-6	MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\jWmlEPTB;MD6xPVI6PSEQvF2=	M2XCWnNCVkeHUh?=
CP66-MEL	M4i3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXNSFZKSzVyPUCuNVk2OzFizszN	M1;acnNCVkeHUh?=
697	NU\sVmM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmH1TWM2OD1yLkG5PVg4KM7:TR?=	MVjTRW5ITVJ?
CP67-MEL	MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDqT5pKSzVyPUCuNlA1QDhizszN	NYDo[FZkW0GQR1XS
DSH1	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIP2[21KSzVyPUCuNlQxODFizszN	M4S3SnNCVkeHUh?=
HCE-4	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTBwMk[0N\|kh\|ryP	M1T1N3NCVkeHUh?=
MZ2-MEL	MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHnTWM2OD1yLkK4OVM4KM7:TR?=	NVXMZmlYW0GQR1XS
BL-41	M2P4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PSd2lEPTB;MD6yPVEzOyEQvF2=	MnXtV2FPT0WU
HUTU-80	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTBwM{G0NkDPxE1?	M2rHWHNCVkeHUh?=
LOXIMVI	NV;xPVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTBwM{G1NFMh\|ryP	M3TlcnNCVkeHUh?=
no-10	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTvOIZKSzVyPUCuN\|E6OzFizszN	MlTJV2FPT0WU
KARPAS-422	NVfLUJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zMXmlEPTB;MD6zN\|k6PyEQvF2=	MVHTRW5ITVJ?
SW684	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTBwM{S5PEDPxE1?	NGrwfHpUSU6JRWK=
SF126	M{XWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPxTWM2OD1yLkO1OFEh\|ryP	MoDQV2FPT0WU
D-263MG	M{fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7LZZBbUUN3ME2wMlM3OjJ2IN88US=>	MlHGV2FPT0WU
OVCAR-4	NF7xe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\MWZRKSzVyPUCuN\|c1OzNizszN	NUfaTZZQW0GQR1XS
BB49-HNC	NVLXRoJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;jTWM2OD1yLkO4OVk6KM7:TR?=	M3OxS3NCVkeHUh?=
ONS-76	NXzQ[Ys{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\NSnQ5UUN3ME2wMlQzQTVzIN88US=>	M17XUHNCVkeHUh?=
MZ7-mel	M3\1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjIeIlKSzVyPUCuOFc6OTFizszN	NYe2cmZjW0GQR1XS
RCC10RGB	NGT5U3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTBwNEmxNUDPxE1?	NXrSWGluW0GQR1XS
BOKU	NInLSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTBwNEmxN\|Mh\|ryP	MnrCV2FPT0WU
no-11	M{P5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;XfY5KSzVyPUCuOVAzOjhizszN	M13tb3NCVkeHUh?=
IST-SL2	NEmz[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\HTohYUUN3ME2wMlUxOzB{IN88US=>	MUPTRW5ITVJ?
RKO	NWj4fJlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTZTWM2OD1yLkWyPVY3KM7:TR?=	NEnvNGVUSU6JRWK=
HT-144	NGfiTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrvepNKSzVyPUCuOVM3ODlizszN	NEXyfG1USU6JRWK=
NCI-H446	NIm5OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTBwNkK3OkDPxE1?	MYTTRW5ITVJ?
QIMR-WIL	MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS2clI2UUN3ME2wMlcxPjJ7IN88US=>	MoPMV2FPT0WU
MHH-PREB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwN{S0Olkh\|ryP	M1\BV3NCVkeHUh?=
EW-16	M1zKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXCTWM2OD1yLke2NVc5KM7:TR?=	MYjTRW5ITVJ?
EW-24	NWHvbnNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTBwN{ixOlUh\|ryP	MVPTRW5ITVJ?
LB373-MEL-D	M3f1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjWU4dKSzVyPUCuPFI2ODhizszN	NVHXSmxjW0GQR1XS
TE-9	M{XGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHq3PZBKSzVyPUCuPFc2OzJizszN	MXrTRW5ITVJ?
A3-KAW	NXvQW4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2C5PGlEPTB;MD65PFQ2OiEQvF2=	NVi0UHNVW0GQR1XS
A101D	NHSwXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTFwMEOwOFMh\|ryP	M3L6NHNCVkeHUh?=
OCUB-M	NHPsN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFwMES0NVIh\|ryP	M4jGdHNCVkeHUh?=
ES4	M3ezWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPSTWM2OD1zLkC1NVQ2KM7:TR?=	NYHjNoJCW0GQR1XS
TE-6	NGjOe\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnFRmdKSzVyPUGuNlEzOjZizszN	NXzTS2VyW0GQR1XS
D-502MG	NXXsOmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3y1TGlEPTB;MT6yN\|M4PiEQvF2=	Mo\qV2FPT0WU
KNS-42	M1:3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmj0TWM2OD1zLkK0OFEzKM7:TR?=	MVnTRW5ITVJ?
SNU-C2B	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLEUlVKSzVyPUGuN\|A2QDlizszN	NUHEOZpvW0GQR1XS
NCI-H1838	NHLIdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fWOmlEPTB;MT6zNFc{OyEQvF2=	M1nvUXNCVkeHUh?=
NKM-1	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\JTWM2OD1zLkOwPFU6KM7:TR?=	NVjLPVRHW0GQR1XS
GI-1	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfkTWM2OD1zLkO2NlIh\|ryP	NUG5fY94W0GQR1XS
NB5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDGR2V4UUN3ME2xMlM6QDJ5IN88US=>	NHfoUGtUSU6JRWK=
CAS-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvHe2ZKSzVyPUGuOFA6QTJizszN	MYPTRW5ITVJ?
HCE-T	MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTFwNU[3NVQh\|ryP	MVnTRW5ITVJ?
SBC-1	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPsTWM2OD1zLkW3PVg1KM7:TR?=	NWW2U2dVW0GQR1XS
JiyoyeP-2003	NGnUNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTFwN{O0OlYh\|ryP	M3S1UHNCVkeHUh?=
TE-5	NYPRRXp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnhdGRSUUN3ME2xMlc6OTN7IN88US=>	MnzPV2FPT0WU
CAN	M1rkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkf2TWM2OD1zLkiyNlUzKM7:TR?=	NH\tcndUSU6JRWK=
SK-UT-1	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjWPZFIUUN3ME2yMlE3Pjl\|IN88US=>	MYHTRW5ITVJ?
JVM-2	NWCybnhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[yPJk{UUN3ME2yMlM3Ojh2IN88US=>	MXjTRW5ITVJ?
LB771-HNC	NV3Pe21rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG[yUYVKSzVyPUKuOVc2PTFizszN	NHHMfnlUSU6JRWK=
NCCIT	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP6eIRKSzVyPUKuPFY3OTZizszN	MnPhV2FPT0WU
NCI-H2126	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPTcW9KSzVyPUKuPFc2PTJizszN	MkXlV2FPT0WU
Calu-6	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvsTWM2OD1\|LkC1O\|QyKM7:TR?=	NWPIcHZFW0GQR1XS
SK-LMS-1	NWXoeWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vwOmlEPTB;Mz6xNVg5PiEQvF2=	M1;RdnNCVkeHUh?=
ARH-77	NIHufYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTNwNE[5NVUh\|ryP	MVfTRW5ITVJ?
NB17	MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYD3XoF[UUN3ME2zMlY{QDR5IN88US=>	MWLTRW5ITVJ?
A253	NEHGbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTNwN{OyOFYh\|ryP	MkDMV2FPT0WU
OPM-2	NHXOfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTRwMke2PFUh\|ryP	M3fMVnNCVkeHUh?=
MV-4-11	NFzNN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljHTWM2OD12LkO2OFU1KM7:TR?=	MX\TRW5ITVJ?
SR	MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTRwNEm5OVQh\|ryP	MnTYV2FPT0WU
KG-1	NHWyOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXvbWlKSzVyPUSuOlA5PDVizszN	MV;TRW5ITVJ?
OCI-AML2	M3[xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\nfIFKSzVyPUWuPFYyPTRizszN	NVux[oNOW0GQR1XS
D-247MG	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4frWmlEPTB;Nj6xNlUyQSEQvF2=	NWPQWWtPW0GQR1XS
DJM-1	NFXrd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DmOGlEPTB;Nj60PFU2QCEQvF2=	MlXvV2FPT0WU
RPMI-6666	M4[0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmThTWM2OD15LkK3NFY4KM7:TR?=	MV3TRW5ITVJ?
KARPAS-45	NVLW[JJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TSVWlEPTB;Nz61NVY4OSEQvF2=	M1vDdnNCVkeHUh?=
LP-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ywbWlEPTB;Nz61OFc5OiEQvF2=	M3XUe3NCVkeHUh?=
RS4-11	M130XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXYTWM2OD15Lk[1O\|g4KM7:TR?=	M1T0SHNCVkeHUh?=
DU-4475	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPGTWM2OD16LkKxOlUzKM7:TR?=	MnXsV2FPT0WU
MONO-MAC-6	M3\1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHPfopQUUN3ME24MlI4ODZ4IN88US=>	NGi3eHpUSU6JRWK=
NCI-SNU-16	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIKyUWFKSzVyPUiuOVYyOjhizszN	NGTuNHNUSU6JRWK=
SJSA-1	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7WcVFUUUN3ME24MlczQDB3IN88US=>	NYH6UW8{W0GQR1XS
MMAC-SF	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWntNXJkUUN3ME24Mlc6OzB5IN88US=>	MlvhV2FPT0WU
SK-NEP-1	M4HKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFu2TnJKSzVyPUiuPFkyPTVizszN	NFfUPXdUSU6JRWK=
J-RT3-T3-5	M2rHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DmZmlEPTB;OD65OlUzQSEQvF2=	MUHTRW5ITVJ?
SKM-1	M335Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHZTWM2OD17LkCxO\|M1KM7:TR?=	M3;ROnNCVkeHUh?=
LB2241-RCC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYH1THdIUUN3ME25MlAzODF{IN88US=>	NIn1To1USU6JRWK=
SIG-M5	M{DDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEm4N\|lKSzVyPUmuNFI1QTNizszN	M2i5cHNCVkeHUh?=
EVSA-T	NHLIRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fBeGlEPTB;OT6yO\|c6OyEQvF2=	MVPTRW5ITVJ?
GT3TKB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrze2FqUUN3ME25MlM2PTR4IN88US=>	M17DcnNCVkeHUh?=
NB6	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jZVmlEPTB;OT65NlI2QSEQvF2=	NH\FfYpUSU6JRWK=
EHEB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDVTmhlUUN3ME2xNE4xPjV4IN88US=>	MnHUV2FPT0WU
HEL	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXIOVlKSzVyPUGwMlQ4PzZizszN	M4TmPXNCVkeHUh?=
ALL-PO	NVrFTYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfjPXBJUUN3ME2xNE44QTN6IN88US=>	NHP1WZJUSU6JRWK=
TGW	NFPCUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP3TWM2OD1zMT6yPFI5KM7:TR?=	MXTTRW5ITVJ?
BC-3	NIK4fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTF{LkGxN\|gh\|ryP	M4DkT3NCVkeHUh?=
IA-LM	NYHReIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTF{LkS0OFUh\|ryP	M2js[nNCVkeHUh?=
UACC-257	M1jabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTF{LkmxPVgh\|ryP	NUHZO2J{W0GQR1XS
KP-N-YS	NGjsVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnWwTWM2OD1zMj65Nlg{KM7:TR?=	NGXKeIpUSU6JRWK=
Raji	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTF\|Lke0PVch\|ryP	MWDTRW5ITVJ?
SF539	NELZd\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DFNWlEPTB;MUOuPFU2PyEQvF2=	MWPTRW5ITVJ?
DMS-153	M{HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1H2UGlEPTB;MUSuNFAzQCEQvF2=	MkHJV2FPT0WU
L-540	NI\tWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{H3UWlEPTB;MUWuNFY4OiEQvF2=	NFu2cnZUSU6JRWK=
MN-60	M4LXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDMclhKSzVyPUG1MlE6PzlizszN	M1e0XnNCVkeHUh?=
RPMI-8866	NYi5[3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2i0b2lEPTB;MUeuOFQ2PCEQvF2=	NFTN[mJUSU6JRWK=
NCI-H510A	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTF7LkO5O\|Mh\|ryP	MmTrV2FPT0WU
NB13	M3:zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnzOGRKSzVyPUG5MlQ5PzdizszN	NGWwcpFUSU6JRWK=
HAL-01	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrmUXcyUUN3ME2xPU44PTR\|IN88US=>	M4X3c3NCVkeHUh?=
NCI-H720	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLyTWM2OD1{MD6yO\|M{KM7:TR?=	MlPrV2FPT0WU
REH	NUXlNWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{C4TWlEPTB;MkCuOlM2PyEQvF2=	MknpV2FPT0WU
KNS-81-FD	M{fRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mom4TWM2OD1{Mz6xOFYh\|ryP	MlX6V2FPT0WU
HC-1	NWWw[FdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3v3d2lEPTB;MkSuOVU2OSEQvF2=	NXzMd2lLW0GQR1XS
NCI-H2141	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWexeFVMUUN3ME2yOE44PzV2IN88US=>	MYHTRW5ITVJ?
MOLT-4	M1nEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1roTWlEPTB;Mk[uOlc2OyEQvF2=	NGHyOlhUSU6JRWK=
OMC-1	M{HFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvvVFNKSzVyPUK3MlE1OjJizszN	NYX3TXZjW0GQR1XS
LC-1F	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7uTWM2OD1{Nz6zNlQ2KM7:TR?=	MkLBV2FPT0WU
NCI-H1304	M1O5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPCcmZKSzVyPUK4MlE3OjhizszN	NUK4dIFXW0GQR1XS
BC-1	NWq3XJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJ6Lk[1NUDPxE1?	MX\TRW5ITVJ?
NCI-H64	NVyzN\|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDFOlJKSzVyPUK5MlYzPTNizszN	M2XG[HNCVkeHUh?=
MOLT-16	NHjUT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTJ7Lk[yPVIh\|ryP	NULTbGxYW0GQR1XS
U-87-MG	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvvTWM2OD1\|MD63OlYh\|ryP	NYXMSVc2W0GQR1XS
GAK	NEixSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXqySoVvUUN3ME2zNU4zPjh4IN88US=>	MnXIV2FPT0WU
ES8	NGXwW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\1RVB[UUN3ME2zNk4yOjV{IN88US=>	MWTTRW5ITVJ?
HCC1599	NETQTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTN{LkOzNlUh\|ryP	NIG5[INUSU6JRWK=
EB-3	NUXXfpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDYU3ZKSzVyPUO0MlMyOTdizszN	MVXTRW5ITVJ?
HCC1187	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjSZZVlUUN3ME2zOU45ODV{IN88US=>	MkLNV2FPT0WU
SK-PN-DW	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfzS21KSzVyPUO2MlE6PDNizszN	M1HudHNCVkeHUh?=
JVM-3	NXfoZnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUntVndmUUN3ME2zO{4zOzN6IN88US=>	MnvXV2FPT0WU
HCC2157	NGDm[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\2VmlEPTB;M{euPVk1PiEQvF2=	NXvNRZRzW0GQR1XS
A4-Fuk	NYr4VFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\Mb5ZKSzVyPUO4MlExODlizszN	M1KwcHNCVkeHUh?=
COR-L279	NWLNVlZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjwRZVKSzVyPUSwMlI5PTFizszN	M1nBcHNCVkeHUh?=
DEL	MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTRzLkmwPFYh\|ryP	NIj2R49USU6JRWK=
NCI-H1395	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjFUXNHUUN3ME20Nk4xOTZ\|IN88US=>	MlzRV2FPT0WU
MHH-NB-11	NETFe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nXfGlEPTB;NEOuNFgyQCEQvF2=	MWPTRW5ITVJ?
NCI-H2107	NX\zW3Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;kPFBKSzVyPUSzMlQ5PDZizszN	M1z0UnNCVkeHUh?=
NEC8	M{LxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DxeGlEPTB;NESuN\|M3KM7:TR?=	MXXTRW5ITVJ?
COLO-684	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkW3TWM2OD12Nj6yNlU5KM7:TR?=	Moq3V2FPT0WU
LS-411N	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLZ[mVnUUN3ME20PE41PzR6IN88US=>	NX;xWYxnW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	BMS-354825
Smiles	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4
NCT04115059	Recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 4 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib